SPI1 and acute myeloid leukemia: Interestingly, PU.1 induction has recently been demonstrated by intravenous cytokine activation,62 and it may be that a small molecule-based therapeutic to upregulate PU.1 and alter downstream target expression will have clinical potential to treat PU.1-dysregulated AML.